Abstract
Objective:Several pathways are known to be activated during metastasis and treatment of cancer. We investigated the role of osteopontin (OPN) and stathmin-1 (STHMN1) in metastatic castrate-resistant (mCRPC).Methods:We included 30 patients who received at least 6 cycles of taxane regimen for metastatic mPC in the present study. For this study retrospective data was taken from Firat University, Faculty of Medicine, Medical Oncology Department between 2009 and 2015. OPN expression and STHMN1 expression were retrospectively evaluated by immunohistochemical staining in biopsy specimens. The relationship between the expression levels of OPN and STMN1 and the response to taxane based regimen and survival was analyzed.Results:There was mild or strong overexpression of OPN and STHMN1 in all the patients. STHMN1 expression was mildly positive (+2) in four of the cases (13.2%) while it was strongly positive (+3) in 25 (83.4%) cases. Similarly, OPN expression was mildly positive (+2) and strongly positive (+3) in five (16.6%) and 25 (87.4%) patients, respectively. There was no significant correlation between the expression levels of STHMN1 and OPN, survival, and response to taxane based regimen (p>0.05); however, OPN overexpression showed a significant correlation with lower Gleason scores (GS) (p:0.032).Conclusions:STHMN1 and OPN may be prognostic markers although they are not predictive markers of response to treatment in mCRPC. The overexpression of OPN may help identifying patients with lower GS.
Highlights
Prostate cancer is the second most common cancer and the leading cause of cancer-related death in men worldwide
The group of responders was evaluated in three categories as patients with response, stable disease and flare phenomenon based on the PSA working group consensus criteria as follows: a) Response: ≥50% PSA reduction from baseline, b) Stable disease:
We investigated whether STHMN1 and OPN expressions could be predictive markers for cancer metastasis and resistance to Taxane based regimen (TBR) in metastatic prostate cancer castre-resistance prostate cancer (mCRPC)
Summary
Prostate cancer is the second most common cancer and the leading cause of cancer-related death in men worldwide. Continuous androgen deprivation therapy (ADT) is recommended as first-line treatment for metastatic and hormone-naive disease. These patients eventually gain resistance to ADT. The level of PSA of patients increase, the levels of testosterone are at castration, and the disease progress in a few years. Chemotherapy (CT) is often recommended in combination with ADT as the initial treatment for metastatic prostate cancer castre-resistance prostate cancer (mCRPC) with high tumor volume.[1]. Taxane based regimen (TBR) is the first option in patients with metastatic prostate cancer. Taxanes inhibit mitosis by decreasing the depolymerization of β-tubulin.[1,2] There are several studies showing improved overall survival (OS) with TBR while some patients may not respond to this treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
